%0 Journal Article
%T A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program
%A Christopher Lucasti
%A Cynthia Kennedy
%A Greg Moeck
%A Jeff Loutit
%A Karen Fusaro
%A Mark Redell
%A Michael Dudley
%A Stephanie Durso
%J Archive of "Open Forum Infectious Diseases".
%D 2018
%R 10.1093/ofid/ofy051
%X Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize its use in patients in the postapproval setting, a patient registry was developed
%K ABSSSI
%K oritavancin
%K registry
%K skin infections
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016411/